EyeGate Pharmaceuticals
EyeGate Pharmaceuticals32About
What does EyeGate Pharmaceuticals do?
EyeGate Pharmaceuticals was a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The company's lead product candidate was EGP-437, which utilized a proprietary iontophoretic drug delivery system. EyeGate underwent a name change to Kiora Pharmaceuticals in November 2021.
What is EyeGate Pharmaceuticals's revenue?
StartupHub estimates EyeGate Pharmaceuticals's annual revenue at $6.5M (range $2.7M to $19.8M, 28% confidence), based on comparable companies in the sector.
What is EyeGate Pharmaceuticals's valuation?
StartupHub estimates EyeGate Pharmaceuticals's effective valuation at $165.5M (range $113.7M to $272.8M, 10% confidence), based on comparable companies in the sector.
How much funding has EyeGate Pharmaceuticals raised?
EyeGate Pharmaceuticals has raised a total of $45M in funding. The most recent round on record is Debt.
Where is EyeGate Pharmaceuticals headquartered?
EyeGate Pharmaceuticals is headquartered in Waltham, United States.
When was EyeGate Pharmaceuticals founded?
EyeGate Pharmaceuticals was founded in 2000.
What industry does EyeGate Pharmaceuticals operate in?
EyeGate Pharmaceuticals operates in Biotech, MedTech, HealthTech, Drug Discovery, Ophthalmology, Pharmaceuticals.
No comments yet. Be the first to share your take.